article thumbnail

Tumour-infiltrating lymphocyte therapy in advanced melanoma superior to ipilimumab 

Hospital Pharmacy Europe

Tumour-infiltrating lymphocyte therapy (TILT) gave rise to superior progression-free survival in comparison to immune checkpoint inhibitor therapy with ipilimumab in a phase 3 trial of patients with advanced melanoma according to the results of a study presented at the European Society for medical Oncology (ESMO) Congress by Dutch researchers.

article thumbnail

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Furthermore, participants who switched from placebo to atacicept in the open-label extension had similar results at 72 weeks as those initially randomised to atacicept in the first 36 weeks.

article thumbnail

EMA finds possible link between mRNA COVID jabs and myocarditis

pharmaphorum

According to the EMA’s pharmacovigilance risk assessment committee (PRAC), labelling for Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax should be updated to reflect “very rare cases” of myocarditis and pericarditis with the shots. . ‘No evidence’ Zynteglo causes blood cancer.

Vaccines 105
article thumbnail

Phase III trial shows tislelizumab improves outcomes for liver cancer patients

European Pharmaceutical Review

Despite improvements in screening, surveillance rules, and imaging, more than two-thirds of patients with HCC present with advanced disease at diagnosis, BeiGene said. The RATIONALE 301 Phase III randomised, open-label study included more than 600 patients in the US, Europe and Asia. About tislelizumab.

article thumbnail

Tuoyi to transform treatment of recurrent/metastatic nasopharyngeal carcinoma

Pharmaceutical Technology

While the data will be presented at an upcoming meeting, a previous analysis of the two arms for OS showed an HR of 0.59, which could lead to a modest but clinically meaningful improvement in OS. Adverse events (AEs) were balanced between the arms, except for immune-related AEs, which were more frequent in the Tuoyi arm (grade ≥ 3, 8.9%

article thumbnail

US FDA grants approval for AstraZeneca’s lung cancer therapy

Pharmaceutical Technology

The approval was based on the findings from the randomised, multicentre, open-label, international Phase III POSEIDON trial. A human monoclonal antibody (mAb), Imfinzi attaches to the PD-L1 protein and hinders its interaction with the PD-1 and CD80 proteins, preventing the immune-evading strategy of the tumour.

FDA 52